The FDA has approved Novartis’s new eye drug brolucizumab for wet age-related macular degeneration, which will match Bayer’s rival Eylea on price per dose but reduce costs with a less frequ
Four big pharma experts explain the challenges companies face in adopting digital tech and what trends are likely to drive digital commercial strategies in the next few years.
